Metropolis Healthcare Q2 profit rises 43% as revenue grows 16%

Metropolis Healthcare Limited reported consolidated profit of Rs 75.483 crore for the quarter ended September 30, 2026, 43% higher year on year, as revenue from operations increased 16% to Rs 496.821 crore. Total expenses rose 12% to Rs 402.832 crore, slower than the increase in revenue, lifting profit before tax to Rs 102.481 crore.

How did Metropolis Healthcare perform in the September quarter?

Metropolis Healthcare’s consolidated profit rose to Rs 75.483 crore in the quarter ended September 30, 2026, from Rs 52.890 crore a year earlier and Rs 56.883 crore in the June 30, 2026 quarter. Profit before tax was Rs 102.481 crore, compared with Rs 71.026 crore in the September 2025 quarter, while total tax expense increased to Rs 26.998 crore from Rs 18.136 crore.

Revenue from operations reached Rs 496.821 crore, against Rs 429.191 crore a year earlier and Rs 450.215 crore in the preceding quarter. Other income was Rs 8.492 crore, compared with Rs 0.891 crore in the September 2025 quarter, taking total income to Rs 505.313 crore. Diluted earnings per share were Rs 3.60, versus Rs 2.53 a year earlier.

What changed in Metropolis Healthcare’s costs and profit?

Metropolis Healthcare’s total expenses increased by Rs 43.776 crore year on year to Rs 402.832 crore, while revenue from operations increased by Rs 67.630 crore. Employee-benefit expense rose to Rs 105.796 crore from Rs 95.393 crore, other expenses increased to Rs 153.895 crore from Rs 132.858 crore, and cost of materials consumed rose to Rs 93.829 crore from Rs 87.748 crore.

Laboratory testing charges were Rs 9.279 crore, up from Rs 4.967 crore, while finance costs rose to Rs 6.986 crore from Rs 5.682 crore. Depreciation and amortisation expense was Rs 33.047 crore, compared with Rs 32.408 crore. There were no exceptional items in either September quarter, whereas the year ended March 31, 2026 included a Rs 8.990 crore exceptional item for estimated past-service gratuity and leave-encashment liabilities.

Metropolis Healthcare reports pathology services as its only reportable segment, so the September 2026 filing does not provide revenue or profit by test category, geography or laboratory format. The consolidated results cover the parent and subsidiaries, including Core Diagnostics Private Limited and Metropolis Healthcare Lanka (Pvt) Limited, alongside overseas step-down subsidiaries.

What do Metropolis Healthcare’s first-half results show?

Metropolis Healthcare generated revenue from operations of Rs 947.036 crore in the six months ended September 30, 2026, compared with Rs 815.255 crore in the corresponding 2025 period. First-half profit rose to Rs 132.366 crore from Rs 98.135 crore, while profit before tax increased to Rs 180.193 crore from Rs 132.256 crore.

Net cash generated from operating activities increased to Rs 222.683 crore in the first half from Rs 129.130 crore a year earlier. Cash flows generated from operations before income taxes were Rs 256.086 crore, compared with Rs 156.588 crore, while net income taxes paid rose to Rs 33.403 crore from Rs 27.458 crore.

Trade receivables increased by Rs 23.973 crore during the six months ended September 30, 2026, less than the Rs 38.284 crore increase in the prior-year period. Purchases of current investments were Rs 326.847 crore and sale proceeds were Rs 204.771 crore, contributing to net investing cash outflow of Rs 144.689 crore, versus Rs 83.688 crore a year earlier.

How did Metropolis Healthcare’s balance sheet change?

Metropolis Healthcare’s total assets rose to Rs 2,340.778 crore at September 30, 2026 from Rs 2,138.055 crore at March 31, 2026. Current assets increased to Rs 636.384 crore from Rs 468.613 crore, led by current investments of Rs 269.361 crore, up from Rs 140.646 crore, and cash and cash equivalents of Rs 68.667 crore, up from Rs 54.784 crore.

Total equity increased to Rs 1,653.294 crore from Rs 1,524.555 crore over the six months, including other equity of Rs 1,600.050 crore compared with Rs 1,471.695 crore. Total liabilities were Rs 687.484 crore, up from Rs 613.500 crore, while current borrowings declined to Rs 17.010 crore from Rs 18.731 crore.

Non-current lease liabilities increased to Rs 176.391 crore at September 30 from Rs 138.265 crore at March 31, alongside right-of-use assets of Rs 230.244 crore compared with Rs 194.715 crore. Goodwill was broadly unchanged at Rs 660.295 crore, while other intangible assets declined to Rs 524.023 crore from Rs 530.830 crore.

What shareholder actions and review findings did Metropolis Healthcare disclose?

Metropolis Healthcare’s board approved an interim dividend of Rs 1 per equity share on 20,75,28,996 shares with a face value of Rs 2 each on November 3, 2026. The audit committee and board approved the September-quarter results on the same date, and Deloitte Haskins & Sells Chartered Accountants LLP issued an unmodified limited-review conclusion.

During the September quarter, the nomination and remuneration committee approved 1,380 restricted stock units, or RSUs, and 20,500 employee stock options under the 2025 plans. Metropolis Healthcare also allotted 1,21,912 RSUs under its 2020 plan during the quarter, after allotting 4,200 RSUs in the June 2026 quarter.

The auditor said two subsidiaries reviewed by other auditors represented total assets of Rs 112.039 crore at September 30, 2026 and quarterly revenue of Rs 35.172 crore. Seven subsidiaries whose interim information was not reviewed by their auditors had assets of Rs 53.903 crore and quarterly revenue of Rs 14.377 crore; management said those entities were not material to the group.

Conclusion

Metropolis Healthcare’s September-quarter results show profit rising faster than revenue, with consolidated profit increasing 43% to Rs 75.483 crore and revenue from operations rising 16% to Rs 496.821 crore. The first-half result also included higher operating cash flow of Rs 222.683 crore and a Rs 128.739 crore increase in total equity from March 31, 2026.

The next disclosed shareholder event is the Rs 1 per-share interim dividend approved on November 3, 2026. Investors can also watch future disclosures on the 20,500 employee stock options and 1,380 RSUs approved under the 2025 plans, as well as the movement in revenue, receivables and operating cash flow after the September half-year.